CLAIMS

We claim:

1. A compound of Formula I



I

wherein

Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-6}alkyl, and C_{1-6}alkoxy, or Ar is 2,3-dihydrobenzfuran-4-yl;

R^1 is C_{1-6}alkyl or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-6}alkyl, and C_{1-6}alkoxy;

or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R^2, R^3, R^4, and R^5 are independently hydrogen, halo, C_{1-3}alkoxy, or C_{1-6}alkyl;

or R^2 and R^3 taken together, R^3 and R^4 taken together, or R^4 and R^5 taken together are $-O(CH_2)_{2-3}-$ or $-O(CH_2)_{1-2}O-$;

R^6 is selected from the group consisting of hydrogen, C_{1-9}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkoxy, C_{1-2}perfluoroalkyl, $-CH_2OC_{1-3}$alkyl, $-(CH_2)_{1-2}CO_2R^7$, $-(CH_2)_{1-2}CO_2NR^7{}_2$, $-NR^7{}_2$, $-CH_2Cl$, $-CH_2OCOMe$, $-CH_2OPh$, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl where phenyl is

optionally substituted with 1-3 substituents selected from halogen, C_{1-3}alkoxy, C_{1-2}perfluoroalkyl, C_{1-2}perfluoroalkoxy, and nitro; and

R^7 is hydrogen or C_{1-6}alkyl;

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

2. The compound of claim 1 where Ar and R^1 are each phenyl optionally substituted with 1-3 substituents selected from halogen, C_{1-6}alkyl, and C_{1-6}alkoxy.

3. The compound of claim 2 where Ar is phenyl or 4-chlorophenyl and R^1 is phenyl.

4. The compound of claim 3 where R^4 is C_{1-3} alkoxy.

5. The compound of claim 4 selected from the group consisting of

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbaldehyde;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6-bromo-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-heptanone;

1-[1-(2-(4-chlorophenyl)-2-phenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-propan-1-one;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-butan-1-one;

cyclopropyl-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-methanone;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-phenyl-methanone;

1-[1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2,2-trifluoro-ethanone;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid amide;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methylamide;

1-(2,2-diphenyl-ethyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid methyl ester; and

1-[1-(2,2-diphenyl-ethyl)-7-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-ethanone;

or a pharmaceutically acceptable salt or solvate thereof.

6. The compound of claim 3 where R^3 and R^4 taken together are $-O(CH_2)_{2-3}-$ or $-O(CH_2)_{1-2}O-$.

7. A method of treatment for circadian-related disorders comprising administration of a therapeutic amount of a compound of Formula Ia



Ia

where:

Ar is phenyl optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-6}alkyl, and C_{1-6}alkoxy, or Ar is 2,3-dihydrobenzfuran-4-yl;

R^1 is hydrogen, C_{1-6}alkyl, or phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-6}alkyl, and C_{1-6}alkoxy;

or Ar and R taken together with the carbon to which they are attached are 1-indanyl or 9-fluorenyl;

R^2, R^3, R^4, and R^5 are independently hydrogen, halo, C_{1-3}alkoxy, or C_{1-6}alkyl;

or R^2 and R^3 taken together, R^3 and R^4 taken together, or R^4 and R^5 taken together are $-O(CH_2)_{2-3}-$ or $-O(CH_2)_{1-2}O-$;

R^6 is selected from hydrogen, C_{1-9}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkoxy, C_{1-2}perfluoroalkyl, $-CH_2OC_{1-3}$alkyl, $-(CH_2)_{1-2}CO_2R^7$, $-(CH_2)_{1-2}CO_2NR^7{}_2$, $-NR^7{}_2$, $-CH_2Cl$, $-CH_2OCOMe$, $-CH_2OPh$, benzyl, 2-thienyl, 2-furanyl, 5-isoxazolyl, 4-biphenyl, naphthyl, 4-(1,2-methylenedioxy)phenyl, and phenyl wherein phenyl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C_{1-3}alkoxy, C_{1-2}perfluoroalkyl, C_{1-2}perfluoroalkoxy, and nitro; and

R^7 is hydrogen or C_{1-6}alkyl;

or a stereoisomer, pharmaceutically acceptable salt, or solvate thereof.

8. A method of treating sleep disorders comprising administration of a therapeutic amount of the compound of claim 7.

9. A composition useful for treating a patient having circadian-related disorders comprising a therapeutic amount of a compound of claim 7 and a pharmaceutically acceptable carrier.

10. A composition useful for treating a patient having sleep disorders comprising a therapeutic amount of a compound of claim 7 and a pharmaceutically acceptable carrier.